Wall Street analysts expect Insulet (PODD) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year decline of 25%. Revenues are expected to be $581. ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...

Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.

Insulet stock opened at $270.81 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $19.02 billion, a P/E ...